What to Expect at the 4th Annual Biologics CDMO Asia
Attendees
Join over 350 professionals at 4th Annual Biologics CDMO Asia! This is your chance to connect with key industry players, expand your network, and engage in high-level discussions that will shape the future of biologics.
Companies
Meet 180 leading companies driving innovation in the biologics sector. Whether you're looking for new partners or exploring the latest breakthroughs, this is the perfect platform to discover what’s next in the industry.
Speakers
Gain exclusive insights from 40 expert speakers who are shaping the future of biologics. Learn from the best in the field as they share cutting-edge knowledge, practical solutions, and emerging trends you can’t afford to miss.
Concept: 4th Annual Biologics CDMO Asia
In 2023, the global biopharma CMO market size reached USD 17.41 billion, with projections to attain USD 39.31 billion by 2031, showcasing a dominant CAGR of 10.72%. Meanwhile, the global CDMO market size stands at USD 15.32 billion in 2024 and is forecasted to grow to USD 27.94 billion by 2029 at a CAGR of 12.78%.
While North America has traditionally dominated the CMO/CDMO market, the Asia-Pacific region has emerged as the fastest-growing. Expected to experience a robust regional CAGR of 8.94% from 2024 to 2029, this growth is driven by a rapidly expanding population demanding biologics. Additional contributing factors include comparatively lower labor costs (up to 30% lower in manufacturing alone), favorable government policies, and regulatory changes.
The 4th Annual Biologics CDMO Asia is a premier event exclusively focused on Contract Manufacturing in the Asia-Pacific region. The conference addresses the growing market of contract manufacturing, predicted market trends, challenges faced by CMOs/CDMOs, and available solutions and opportunities for future growth.
We bring the entire ecosystem together — from experts in the biologics manufacturing space, academia, and regulatory authorities — to foster partnerships, share insights, and stay at the forefront of new developments.
WHO
This conference is designed for high-level professionals, including C-Suite Executives, Heads, Presidents, Directors, and Vice Presidents involved in Manufacturing, Bioprocessing Downstream Processing, Upstream Processing, and External Manufacturing. Participants come from a diverse range of biologics manufacturing companies across the Asia-Pacific (APAC) region and beyond, representing both established industry leaders and innovative emerging players.
WHAT
The conference aims to provide a comprehensive platform to evaluate and explore the latest strategies, technologies, and solutions in the field of biologics manufacturing. This includes a deep dive into high-speed and resilient biologics production processes, with a special focus on technological advancements, quality control, regulatory compliance, and operational excellence. Attendees will gain insights into how these innovations are being applied throughout Asia’s clinical trials and rapidly evolving markets, ensuring biologics manufacturing can keep pace with growing demand and technological advancements.
WHY
The contract manufacturing company segment presents a vast array of lucrative opportunities for growth and expansion. As the demand for biologics continues to rise, the Asia-Pacific Biologics CDMO market is projected to experience substantial growth, with an annual rate of 8.3%, reaching a total addressable market cap of USD 752.2 Billion by 2030. The potential for innovation, partnerships, and investment in the region is immense, driven by factors such as cost efficiencies, favorable regulatory environments, and technological progress. By attending this event, participants can position themselves at the forefront of these exciting developments and capitalize on emerging opportunities.
Contact
Patrick Lim Ming Yau, Conference Producer
[email protected] | +65 6964 7925
Charmaine Poh, Business Development Manager
[email protected] | m: +65 6983 6133
Share With Your Network
